Consensus was also achieved for statement 9, which proposes BRAF-targeted therapy as an alternative neoadjuvant treatment for resectable stage IIIA-IIID melanoma harboring a BRAF V600 mutation for whom ICI therapy is contra-indicated. Here, BRAF is linked to melanoma.